Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Vern Norviel, JD, MS, to its Advisory Board. A highly respected attorney and strategist in biotechnology and intellectual property law, Norviel brings decades of experience advising companies and investors at the forefront of life science innovation.
“Vern’s rare ability to blend deep legal acumen with scientific and business insight makes him a tremendous asset to Orbit,” said Dede Willis, CEO of Orbit Genomics. “His perspective will be instrumental as we continue to shape our IP strategy and build global partnerships across diagnostics and precision health.”
Norviel is a Partner Emeritus at Wilson Sonsini Goodrich & Rosati and has served in executive leadership roles, including Senior Vice President and General Counsel at Affymetrix. His clients span therapeutics, diagnostics, nanotechnology, genomics, and personalized medicine, and include top-tier venture capital firms and startups alike.
A pioneer in the field, Norviel was the first attorney to publicly have his entire genome sequenced, a testament to his commitment to advancing the life sciences. He is consistently recognized as one of the leading attorneys in the biotechnology sector and has helped shape IP strategy for many of the most influential companies in the industry.
“I’m honored to join Orbit’s Advisory Board at such an exciting time in its evolution,” said Norviel. “OrbiSeq’s innovative platform is uncovering a new layer of genomic information that has the potential to transform preventive healthcare. I look forward to supporting the team as they advance their science and expand their impact.”